Clinical Trial Detail

NCT ID NCT03740165
Title Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/KEYLYNK-001)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

peritoneum cancer

fallopian tube cancer

ovary epithelial cancer


Bevacizumab + Carboplatin + Paclitaxel

Carboplatin + Paclitaxel

Carboplatin + Paclitaxel + Pembrolizumab

Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab

Carboplatin + Olaparib + Paclitaxel + Pembrolizumab

Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.